Roger Stupp MDPaul C. Bucy Professor of Neurological Surgery; Professor of Medicine (Hematology/Oncology) and Neurology, Northwestern University Feinberg School of Medicine; Co-Director, Northwestern Medicine Malnati Brain Tumor Institute; Associate Director for Strategic Initiatives, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois
Dr. Roger Stupp is an internationally recognized neuro-oncologist and a leading authority on primary and metastatic brain cancer. He serves as Professor and Medical Director of the Malnati Brain in the Department of Neurological Surgery, and Division chief of Neuro-Oncology in the Department of Neurology as well as Associate Director for Strategic Initiatives at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago.
Prior to joining Northwestern, Dr. Stupp was Professor of Oncology at the University of Zürich, Switzerland where he led the Department of Oncology and the Cancer Center of the University of Zürich Hospital as its director from 2013 - 2017. He dedicated a large part of his career to developing multidisciplinary centers of excellence and integrated clinical and translational research at the University Hospital of Lausanne (CHUV), Switzerland, where he served in different functions from 1996 to 2013. Since 2006 he serves on the board of the European Organisation for Research and Treatment of Cancer, from 2012 – 2017 as the president.
Dr. Stupp is an active and dedicated clinical researcher. His special clinical interests include the multimodality management of primary and secondary brain tumors, head and neck tumors, and lung cancers, as well as new drug development and the association of chemotherapy and radiation therapy. He is also closely involved in bringing new antiangiogenic and biological treatments to the clinic. He is part of Northwestern Universities Brain Tumor SPORE leadership and he maintains close collaborations with its basic and translational research laboratories.Dr. Stupp reported in 2009 on a curative approach for treating locally advanced, “inoperable” stage IIIB non−small cell lung cancer with a multimodality treatment approach including neoadjuvant chemotherapy and radiotherapy followed by definitive surgery.
Dr. Roger Stupp was the lead investigator for establishing the use of temozolomide chemotherapy in conjunction with radiotherapy in patients with newly diagnosed glioblastoma. In this seminal work Drs Stupp and Hegi also demonstrated the predictive value of MGMT gene-promoter methylation, a biomarker that has since become standard. Other work and randomized trials included investigation of the integrin inhibitor cilengitide, EGFRviii vaccination with rindopepimut, and establishing alternating electrical fields (Tumor Treating Fields) as a novel treatment or modality in glioblastoma.
Professor of Medicine (Hematology/Oncology), Neurology and Neurological Surgery, Northwestern University Feinberg School of Medicine; Co-Director, Northwestern Medicine Malnati Brain Tumor Institute, Departments of Neurological Surgery and Neurology; Division Chief for Neuro-Oncology, Department of Neurology; Associate Director for Strategic Initiatives, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago Illinois.
MD: University ofZürich Medical School, Zürich, Switzerland
Fellowship (medicine and hematology/oncology): University of Chicago Hospitals and Cancer Center, Chicago, Illinois
Multimodality management of primary and secondary brain tumors, head and neck tumors, and lung cancers
Dr. Stupp serves as an advisor to Celularity Inc, GT Medical Technology Inc, and DNAtrix Inc, Northwest Biotherapeutics Inc and several non-clinical stage biotech companies.
Recent Contributions to PracticeUpdate:
- Ineffectiveness of High‐Dose Methotrexate for Prevention of CNS Relapse in DLBCL
- Comparison of Temozolomide and Radiotherapy on Memory Outcomes Among Patients With Low-Grade Glioma
- Radiotherapy Dose-Intensification Using IMRT vs Standard Dose RT in Newly-Diagnosed GBM
- Oncolytic Adenovirus in Combination With Pembrolizumab for Recurrent Glioblastoma
- Optimizing Drug Development for Glioma
- Key Takeaways From ESMO: Enhancing Prognostication for Glioblastoma
- Intracranial Efficacy of Entrectinib Among Patients With NTRK Fusion-Positive CNS Metastases
- ASCO: Olutasidenib for Relapsed/Refractory IDH1 Mutant Glioma
- ASCO: FAK Inhibition for Meningiomas With NF2 Mutations
- ASCO 2020: Abstract Recommendations From Dr. Roger Stupp for Brain Cancer